SBIR/STTR Research Award

Vision Restoration with Photoswitch Technology

Award identifier 3a2685da501553f351efcb31b638c769e74d64c2fa2442077a27b3c3a0282325Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$1,436,613

Program and phase

SBIR · Phase II

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PHOTOSWITCH BIOSCIENCES, INC.
Proposal award date
2015-02-01
Contract end date
2019-01-31
UEI
Not reported
Solicitation number
PA14-071
Topic code
N

Research abstract

DESCRIPTION provided by applicant The goal this project is to restore vision to persons with degenerative diseases of the retina The target patient population are currently living with very limited or no sight and include persons with retinitis pigmentosa RP and age related macular degeneration AMD RP is an inherited disorder affecting approximately people in the US that is typically diagnosed in adolescents and young adults Approximately one quarter of all persons with RP become legally blind in both eyes AMD is a relatively common affliction affecting approximately ten million Americans and it is the leading cause of blindness in Americans years and older Early detection and treatment of macular degeneration may help reduce vision loss but does not restore vision There are no treatments that can restore moderate to high acuity vision to these persons The present proposal comprises candidate selection experiments for a small molecule therapeutic Specifically we propose making high purity batches of our candidate photoswitch compounds formulate those compounds for delivery to the back of the eye and complete a series of operant conditioning vision restoration efficacy studies in rat models of RP Based on those results we will select a single compound and formulation for thorough characterization in pharmacokinetic PK studies in rat and rabbit and in in vitro and in vivo safety studies Successful completion of the presen project will allow us to have a fully informed pre IND meeting with the FDA raise monies from private sources to fund the IND enabling GLP safety studies file an IND and initiate a Phase clinical trial in the target patient population Such a clinical trial will provide a clear indiction of the efficacy of the compound in man PUBLIC HEALTH RELEVANCE The goal of the present project is to develop a therapeutic that would restore vision to persons with advanced retinitis pigmentosa RP and age related macular degeneration AMD RP and AMD are progressive degenerative diseases of the retina that result in low vision and blindness There are currently no treatments that can restore moderate or high acuity vision to these persons

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.